Delving into the Latest Updates on TB-B002D with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TB B002D, TB-B002D, TBB002D

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Idiopathic Pulmonary FibrosisLung Injury

Inactive Indication-

Originator Organization

Shenzhen Turier Biotech Co., Ltd.

Active Organization

Shenzhen Turier Biotech Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价TB-B002D注射液在健康受试者单次皮下注射给药后的安全性和耐受性。次要目的：评价TB-B002D注射液在健康受试者单次皮下注射给药后的药代动力学（PK）特征。评价TB-B002D注射液在健康受试者单次皮下注射给药后的免疫原性特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of TB-B002D injection after a single subcutaneous injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of TB-B002D injection after a single subcutaneous injection in healthy subjects. To evaluate the immunogenicity characteristics of TB-B002D injection after a single subcutaneous injection in healthy subjects.

Start Date18 May 2023

Sponsor / Collaborator

Shenzhen Turier Biotech Co., Ltd.

100 Clinical Results associated with TB-B002D

Login to view more data

100 Translational Medicine associated with TB-B002D

Login to view more data

100 Patents (Medical) associated with TB-B002D

Login to view more data

100 Deals associated with TB-B002D

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Phase 1	China	Shenzhen Turier Biotech Co., Ltd.	18 May 2023
Lung Injury	IND Approval	China	Shenzhen Turier Biotech Co., Ltd.	10 Nov 2023